Southpoint Capital Advisors LP Buys New Position in IQVIA Holdings Inc. $IQV

Key Points

• Southpoint Capital Advisors LP has acquired a new stake in IQVIA Holdings Inc., purchasing 300,000 shares worth approximately $52.89 million, which constitutes about 1.2% of its portfolio.
• IQVIA's stock is currently valued at $190.71 per share, with analysts expecting a consensus EPS of 10.84 for the current year.
• Several institutional investors have significantly increased their holdings in IQVIA, with 89.62% of the stock now owned by institutional investors.

Southpoint Capital Advisors LP bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 300,000 shares of the medical research company's stock, valued at approximately $52,890,000. IQVIA accounts for approximately 1.2% of Southpoint Capital Advisors LP's holdings, making the stock its 27th largest position. Southpoint Capital Advisors LP owned approximately 0.17% of IQVIA as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. American National Bank & Trust acquired a new position in shares of IQVIA during the first quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd boosted its stake in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after purchasing an additional 131 shares in the last quarter. Golden State Wealth Management LLC increased its position in shares of IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the period. AllSquare Wealth Management LLC bought a new stake in shares of IQVIA in the 1st quarter worth $33,000. Finally, ST Germain D J Co. Inc. lifted its holdings in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

IQVIA stock opened at $190.71 on Tuesday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The firm's 50 day simple moving average is $177.74 and its 200-day simple moving average is $167.49. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $32.42 billion, a P/E ratio of 27.60, a price-to-earnings-growth ratio of 2.09 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter in the prior year, the firm earned $2.64 EPS. The firm's quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on IQV shares. Barclays lifted their target price on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Robert W. Baird lifted their price objective on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Redburn Partners set a $188.00 target price on shares of IQVIA in a research note on Friday, May 23rd. William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Truist Financial upped their price target on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $228.62.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.